Nektar Therapeutics (NASDAQ:NKTR) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 11, Wedbush analyst Martin Fan decreased the price target on Nektar Therapeutics (NASDAQ:NKTR) from $95 to $80 while reiterating a Neutral rating. This revision is followed by the recent corporate earnings report, where Nektar has reaffirmed forward-looking guidance across its broader product portfolio.
RAJ CREATIONZS / shutterstock.com
Additionally, the company has confirmed that by July 2026, it will be initiating the Phase 3 ZENITH-AD program for rezpegaldesleukin, which is used to treat atopic dermatitis. Despite this clinical progression, the analyst is still quite uncertain about the possibility of significant first-line market penetration.
Fan believes that Dupixent’s well-established commercial dominance is a major factor in this cautious approach. Furthermore, within two years of any prospective rezpegaldesleukin launch alternative biosimilars are expected to enter the market, posing a threat to the competitive environment.
On May 8, while retaining an Overweight rating on the stock, Yasmeen Rahimi from Piper Sandler increased the firm’s price target on Nektar Therapeutics (NASDAQ:NKTR) from $105 to $192. The adjustments lead to a highly lucrative upside potential of over 200% at the prevailing level.
The firm noted that Nektar disclosed its first quarter results and provided an update on REZPEG’s Phase 3 ZENITH-AD program design, which will comprise five trials in total. The two biologic-naive AD studies will begin in July 2026, and the first ZENITH-AD readout will occur in mid-2028. Additionally, a third trial with AD patients with biologic experience is included in ZENITH-AD, with commencement taking place some months after biologic naive.
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that discovers and develops drugs targeting immunological dysfunctions. It develops rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255. These are used to treat autoimmune disorders, ulcerative colitis, and multiple sclerosis, autoimmune diseases, fibrotic diseases, and solid tumors/large B-cell lymphoma, respectively.
While we acknowledge the risk and potential of NKTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NKTR and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
